ClinicalTrials.Veeva

Menu

Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds

Abbott logo

Abbott

Status

Completed

Conditions

Ventricular Arrythmias
Heart Failure

Treatments

Device: Testing of the autocapture features of the device

Study type

Interventional

Funder types

Industry

Identifiers

NCT00746356
Doc number 40005027 (Other Identifier)
IDE # G080060 (Other Identifier)
40005027

Details and patient eligibility

About

This study is a prospective, non-randomized, multi-center clinical trial that will assess the safety and effectiveness of investigational models of the Promote™ RF CRT-D and Current™ RF ICD devices. These new ICD and CRT-D devices have new features that allow the device to periodically check how much energy is needed to pace a patient's heart and to automatically adjust the amount of energy used to pace the heart.

Full description

All patients enrolled in the study will have their device tested to determine if the device can automatically measure how much energy is needed to pace the patient's heart. If the test is successful, the patient's device will be programmed to turn that feature on. 3 months after enrollment, the patient will return to the clinic to have their device re-tested using an automatic test method to measure the amount of energy needed to make the patient's heart beat. A manual test method will also be used to measure the amount of energy needed to make the patient's heart beat. The intent of the study is to show the automatic method works just as well as the manual method.

Enrollment

128 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have an approved indication, as outlined by American Heart Association/Heart Rhythm Society (AHA/HRS) guidelines, for implantation of an ICD or CRT-D for the treatment of life-threatening ventricular tachyarrhythmia(s) or heart failure, or undergo revision of their ICD or CRT-D system to replace the pulse generator.
  • Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations.

Exclusion criteria

  • Have a classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 3 months.
  • Have had a recent myocardial infarction, unstable angina or cardiac revascularization (percutaneous transluminal coronary angioplasty (PTCA), Stent or Coronary Artery Bypass Graft(CABG)) within 40 days of enrollment.
  • Have had a recent cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 3 months of enrollment.
  • Are allergic to dexamethasone sodium phosphate (DSP).
  • Be currently participating in a clinical investigation that includes an active treatment arm.
  • Be pregnant or are planning for pregnancy within 6 months following enrollment.
  • Have a life expectancy of less than 6 months.
  • Be less than 18 years of age.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

128 participants in 2 patient groups

Promote RF CRT-D
Experimental group
Description:
Patients with CRT-D device will have the autocapture features of the device tested.
Treatment:
Device: Testing of the autocapture features of the device
Device: Testing of the autocapture features of the device
Current RF ICD
Experimental group
Description:
Patients with ICD device will have the autocapture features of the device tested.
Treatment:
Device: Testing of the autocapture features of the device
Device: Testing of the autocapture features of the device

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems